Spesolimab for treating generalised pustular psoriasis flares: a single technology appraisal
Spesolimab for treating generalised pustular psoriasis flares: a single technology appraisal
This report is a critique of the company’s submission (CS) to NICE from Boehringer
Ingelheim Ltd on the clinical effectiveness and cost effectiveness of spesolimab (Spevigo) for treating adults with generalised pustular psoriasis presenting with flares. It identifies the strengths and weaknesses of the CS.
Southampton Health Technology Assessments Centre
Ribeiro, Ines
2fd1901b-61bd-4ad5-81b3-a3f8145ec144
Woods, Lois
8149aa11-7664-4052-a18b-98f7bde83180
Hawa, Asyl
64ce4257-6176-4a4e-bce5-5e1147377355
Picot, Jo
324d6f20-a105-49fd-9fb0-88791be84ada
2024
Ribeiro, Ines
2fd1901b-61bd-4ad5-81b3-a3f8145ec144
Woods, Lois
8149aa11-7664-4052-a18b-98f7bde83180
Hawa, Asyl
64ce4257-6176-4a4e-bce5-5e1147377355
Picot, Jo
324d6f20-a105-49fd-9fb0-88791be84ada
Ribeiro, Ines, Woods, Lois, Hawa, Asyl and Picot, Jo
(2024)
Spesolimab for treating generalised pustular psoriasis flares: a single technology appraisal
Southampton Health Technology Assessments Centre
133pp.
Record type:
Monograph
(Project Report)
Abstract
This report is a critique of the company’s submission (CS) to NICE from Boehringer
Ingelheim Ltd on the clinical effectiveness and cost effectiveness of spesolimab (Spevigo) for treating adults with generalised pustular psoriasis presenting with flares. It identifies the strengths and weaknesses of the CS.
Text
Spesolimab EAG report
- Other
More information
Published date: 2024
Identifiers
Local EPrints ID: 506633
URI: http://eprints.soton.ac.uk/id/eprint/506633
PURE UUID: 37f32cc5-edef-4066-9685-43d9631fe40b
Catalogue record
Date deposited: 12 Nov 2025 17:46
Last modified: 13 Nov 2025 02:57
Export record
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics